A phase II trial of tideglusib in alzheimer's disease

Journal of Alzheimer's Disease

Volumn 45, Issue 1, 2015, Pages 75-88

  Lovestone, Simon ^a   Boada, Mercè ^b   Dubois, Bruno ^c   Hüll, Michael ^d   Rinne, Juha O ^e   Huppertz, Hans Jürgen ^f   Calero, Miguel ^g   Andrés, María V ^h   Gómez Carrillo, Belén ^h   León, Teresa ⁱ   Del Ser, Teodoro ⁱ  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Institut Catala de Neurociencies Aplicades   (Spain)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF FREIBURG   (Germany)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f SWISS EPILEPSY CENTER   (Switzerland)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h Clinical Department   (Spain)

ⁱ AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Alzheimer's disease; GSK 3; pharmacological treatment; randomized controlled clinical trial; tideglusib

Indexed keywords

AMINOTRANSFERASE; AMYLOID BETA PROTEIN; BETA SECRETASE 1; CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO; TAU PROTEIN; TIDEGLUSIB; 4 BENZYL 2 METHYL 1,2,4 THIAZOLIDINE 3,5 DIONE; APOLIPOPROTEIN E; NEUROPROTECTIVE AGENT; THIADIAZOLE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BEHAVIOR; BRAIN ATROPHY; CEREBROSPINAL FLUID; COGNITION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; CLINICAL TRIAL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PSYCHIATRIC STATUS RATING SCALES; THIADIAZOLES;

EID: 84924106368     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141959     Document Type: Article

References (50)

1. Jope RS, Johnson GV (2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29, 95-102.
2. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439.
3. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, DalfoE, Avila J (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2, 1-3.
4. Wang JZ, Grundke-Iqbal I, Iqbal K (2007) Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 25, 59-68.
5. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27-39.
6. Ishizawa T, Sahara N, Ishigu K (2003) Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. AmJ Pathol 163, 1057-1067.
7. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58, 1010-1019.
8. Ferrer I, Barrachina M, Puig B (2002) Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 104, 583-591.
9. Leroy K, Boutajangout A, Authelet M, Woodgett JR, Anderton BH, Brion JP (2002) The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol 103, 91-99.
10. Akiyama H, ShinRW, Uchida C, KitamotoT, UchidaT (2005) Pin1 promotes production of Alzheimer's amyloid beta from beta-cleaved amyloid precursor protein. Biochem Biophys Res Commun 336, 521-529.
11. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439.
12. Beurel E, Jope RS (2010) Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience 169, 1063-1070.
13. Wang X, She H, Mao Z (2009) Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis. J Biol Chem 284, 32619-32626.
14. Wang X, She H, Mao Z (2009) Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis. J Biol Chem 284, 32619-32626.
15. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K (2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120, 137-149.
16. Hooper C, Markevich V, Plattner F, Killick R, Schofield E, Engel T, Hernandez F, Anderton B, Rosenblum K, Bliss T, Cooke SF, Avila J, Lucas JJ, Giese KP, Stephenson J, Lovestone S (2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25, 81-86.
17. Ratan V, Bhat RV, Haeberlein SLB, Avila J (2004) Glycogen synthase kinase 3: A drug target for CNS therapies. J Neurochem 89, 1313-1317.
18. Medina M, Castro A (2011) Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel 11, 533-543.
19. Su Y, Ryder J, Li B, Wu X, Fox N, Solenberg P, Brune K, Paul S, Zhou Y, Liu F, Ni B (2004) Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43, 6899-6908.
20. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 45, 1292-1299.
21. Domńguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M (2012) Evidence for the irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 287, 893-904.
22. Serenó L, Coma M, Rodríguez M, Sánchez-Ferrer P, Sánchez MB, Gich I, Agulló JM, Pérez M, Avila J, Guardia-Laguarta C, Clarimón J, LleóA, Gómez-Isla T (2009)Anovel GSK-3βinhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 35, 359-367.
23. DaRocha-Souto B, Coma M, Pérez-Nievas BG, Scotton TC, Siao M, Sánchez-Ferrer P, Hashimoto T, Fan Z, Hudry E, Barroeta I, Serenó L, Rodrguez M, Sánchez MB, Hyman BT, Gómez-Isla T (2012) Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis 45, 425-437.
24. Luna-Medina R, Cortes-Canteli M, Sanchez-Galiano S, Morales-Garcia JA, Martinez A, Santos A, Perez-Castillo A (2007) NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: Potential therapeutic role in brain disorders. J Neurosci 27, 5766-5776.
25. Del Ser T, Steinwachs KC, Gertz HJ, Andrés MV, Gómez-Carrillo B, Medina M, Vericat JA, Redondo P, Fleet D, León T (2013) Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: A pilot study. J Alzheimers Dis 33, 205-215.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
27. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12, 189-198.
28. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P (2001) A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 32, 1318-1322.
29. Sheikh JI, Yesavage JA (1986) Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. In: Clinical Gerontology: A Guide to Assessment and Intervention. The Haworth Press, New York, pp. 165-173.
30. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of anti-dementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), 13-21.
31. GalaskoD, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S (1997) An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2), S33-S39.
32. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
33. Rabin R, De Charro F (2001) EQ-5D: A measure of health status from the EuroQol Group. Ann Med 33, 337-343.
34. Guy W (1976) Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM) National Institute for Mental Health. Rockville, pp. 218-222.
35. Sandvik H, Hunskaar S, Seim A, Hermstad R, Vanvik A, Bratt H (1993) Validation of a severity index in female urinary incontinence and its implementation in an epidemiological survey. J Epidemiol Community Health 47, 497-499.
36. Huppertz HJ, Kroll-Seger J, Kloppel S, Ganz RE, Kassubek J (2010) Intra- and interscanner variability of automated voxelbased volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage 49, 2216-2224.
37. Gonzales A, Decourt B, Walker A, Condjella R, Nural H, Sabbagh MN (2011) Development of a specific ELISA to measure BACE1 levels in human tissues. J Neurosci Methods 202, 70-76.
38. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and research (CBER) (2009) The Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Drug Safety. Silver Spring.
39. Pera M, Alcolea D, Sánchez-Valle R, Guardia-Laguarta C, Colom-Cadena M, Badiola N, Suárez-Calvet M, Lladó A, Barrera-Ocampo AA, Sepulveda-Falla D, Blesa R, Molinuevo JL, Clarimón J, Ferrer I, Gelpi E, Lleó A (2013) Distinct patterns ofAPPprocessing in theCNSin autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol 125, 201-213.
40. Barao S, Zhou L, Adamczuk K, Vanhoutvin T, Van Leuven F, Demedts D, Vijverman AC, Bossuyt X, Vandenberghe R, De Strooper B (2013) BACE1 levels correlate with phospho-tau levels in human cerebrospinal fluid. Curr Alzheimer Res 10, 671-678.
41. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol 65, 1102-1107.
42. PerneczkyR, Alexopoulos P; Alzheimer's Disease Euroimaging Initiative (2014) Cerebrospinal fluid BACE1 activity and markers of amyloid precursor protein metabolism and axonal degeneration in Alzheimer's disease. Alzheimers Dement 10 (5Suppl), S425-S429.e1.
43. Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi XP, King E, Devanarayan V, Cook JJ, Simon AJ (2008) Decrease in age-adjusted cerebrospinal fluid betasecretase activity in Alzheimer's subjects. Clin Biochem 41, 986-996.
44. Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, ShenY, HampelH (2008) Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 131, 1252-1258.
45. Ly PT, Wu Y, Zou H, Wang R, Zhou W, Kinoshita A, Zhang M, Yang Y, Cai F, Woodgett J, Song W (2013) Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimerassociated phenotypes. J Clin Invest 123, 224-235.
46. Yu F, Zhang Y, Chuang DM (2012) Lithium reduces BACE1 overexpression, aβ amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma 29, 2342-2351.
47. Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T (2014) A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord 29, 470-478.
48. Höglinger GU, Huppertz HJ, Wagenpfeil S, Andrés MV, Belloch V, León T, Del Ser T (2014) Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 29, 479-487.
49. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study, Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370, 311-321.
50. Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G (2014) Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: The way forward. Expert Rev Clin Immunol 10, 405-419.